Fiona McDonnell

Professor Fiona McDonnell is a distinguished figure in the field of Ophthalmology & Visual Science, currently serving as an Assistant Professor at the University of Utah's Neuroscience Program. Her academic journey began with a Ph.D. from University College Dublin, followed by extensive postdoctoral research at Duke University. This rich academic background has equipped her with a profound understanding of glaucoma pathophysiology, a primary focus of her research endeavors. Professor McDonnell's research is particularly centered on unraveling the complex mechanisms that drive the progression of glaucoma, a leading cause of irreversible blindness worldwide. Her work is pivotal in advancing patient treatment by delving into the intricate roles of extracellular vesicles (EVs). These vesicles are crucial in regulating the extracellular matrix within the outflow pathway and optic nerve head, areas critical to the disease's pathology. A significant aspect of her research involves the innovative use of EVs as biomarkers. By identifying these markers, Professor McDonnell aims to facilitate early detection of glaucoma, which is essential for effective intervention and management. Her approach not only promises to enhance diagnostic accuracy but also paves the way for the development of targeted treatment strategies, potentially transforming patient outcomes. To achieve her research objectives, Professor McDonnell employs a custom-built system designed to study the functional capabilities of the conventional outflow pathway in human tissue. This system allows for a detailed analysis of the physiological processes involved, providing insights that are crucial for understanding and combating glaucoma. Beyond her research, Professor McDonnell is committed to mentoring the next generation of scientists. She actively engages with students and colleagues, fostering an environment of collaboration and innovation. Her dedication to both research and education underscores her reputation as a leader in her field, continually pushing the boundaries of what is known about glaucoma and its treatment.